UB Paderborn / Katalog / Suche / in CDI

Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations

Journal of clinical oncology, 2024-04, Vol.42 (10), p.1158

2024

Volltextzugriff (PDF)

Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study

The Lancet. Haematology, 2019-05, Vol.6 (5), p.e276-e284

2019

Volltextzugriff (PDF)

Association of chronic diseases with mortality among hospitalized patients with COVID-19 treated with convalescent plasma: Evidence from a single center – Iraq

Journal of emergency medicine, trauma & acute care, 2022-03, Vol.2022 (2)

2022

Volltextzugriff (PDF)

The Use of Recombinant Factor VIIa in Controlling Surgical Bleeding in Non-Haemophiliac Patients

Pathophysiology of haemostasis and thrombosis, 2002-01, Vol.32 (1), p.41-46

Aldouri, Maadh

2002

Volltextzugriff (PDF)

Impact of Finding of Low Level Kinase Domain Mutations Using Ultra Deep Next Generation Sequencing in Patients with Chronic Phase CML

Blood, 2015-12, Vol.126 (23), p.347-347

2015

Volltextzugriff (PDF)

Outcomes in Relapsed Multiple Myeloma in the UK: A Retrospective Observational Study

Blood, 2008-11, Vol.112 (11), p.4689-4689

2008

Volltextzugriff (PDF)

Relapsed multiple myeloma in the UK prior to the introduction of novel agents - a response to Koleva. (2010)

European journal of cancer care, 2011-09, Vol.20 (5), p.697

2011

Volltextzugriff (PDF)

Relapsed multiple myeloma in the UK prior to the introduction of novel agents – a response to Koleva et al. (2010)

European journal of cancer care, 2011-09, Vol.20 (5), p.697-699

2011

Volltextzugriff (PDF)

Relapsed multiple myeloma in the UK prior to the introduction of novel agents - a response to Koleva et al. (2010): Letter to the editor

European journal of cancer care, 2011-09, Vol.20 (5), p.697-699

2011

Volltextzugriff (PDF)

Relapsed multiple myeloma in the UK prior to the introduction of novel agents - a response to

European journal of cancer care, 2011-09, Vol.20 (5), p.697-699

2011

Volltextzugriff (PDF)

Defining the Landscape of Resistance Mutations in the Context of Modern Treatment Protocols for Acute Promyelocytic Leukemia (APL)

Blood, 2008-11, Vol.112 (11), p.1492-1492

2008

Volltextzugriff (PDF)

Anti-C(w) alloimmunization presenting as hydrops fetalis

Acta pædiatrica (Oslo), 2005-04, Vol.94 (4), p.499-501

2005

Volltextzugriff (PDF)

Gemtuzumab Ozogamicin with Donor Leucocyte Infusions Is Safe and Effective Therapy for a Subgroup of Relapsed Acute Myeloid Leukaemia and Myelodysplastic Syndrome Following Allogeneic Haemopoietic Stem Cell Transplantation (HSCT)

Blood, 2004-11, Vol.104 (11), p.1806-1806

2004

Volltextzugriff (PDF)

Editorial

Transfusion alternatives in tranfusion medicine, 2003-12, Vol.5 (s5)

2003

Volltextzugriff (PDF)

Editorial

Transfusion alternatives in tranfusion medicine, 2003-12, Vol.5 (s5), p.i-ii

2003

Volltextzugriff (PDF)

Editorial

Transfusion alternatives in tranfusion medicine, 2003-12, Vol.5, p.i-ii

2003

Volltextzugriff (PDF)

Anti-Cw alloimmunization presenting as hydrops fetalis

Acta Paediatrica, 2005-04, Vol.94 (4), p.499-501

2005

Volltextzugriff (PDF)

1,2-DIMETHYL-3-HYDROXYPYRID-4-ONE, AN ORALLY ACTIVE CHELATOR FOR TREATMENT OF IRON OVERLOAD

The Lancet (British edition), 1987-06, Vol.329 (8545), p.1294,e1,e2,1295-1294,e1,e2,1295

1987

Volltextzugriff (PDF)

Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one

British medical journal (Clinical research ed.), 1987-12, Vol.295 (6612), p.1509

1987

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations

Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study

Association of chronic diseases with mortality among hospitalized patients with COVID-19 treated with convalescent plasma: Evidence from a single center – Iraq

The Use of Recombinant Factor VIIa in Controlling Surgical Bleeding in Non-Haemophiliac Patients

Impact of Finding of Low Level Kinase Domain Mutations Using Ultra Deep Next Generation Sequencing in Patients with Chronic Phase CML

Outcomes in Relapsed Multiple Myeloma in the UK: A Retrospective Observational Study

Relapsed multiple myeloma in the UK prior to the introduction of novel agents - a response to Koleva. (2010)

Relapsed multiple myeloma in the UK prior to the introduction of novel agents – a response to Koleva et al. (2010)

Relapsed multiple myeloma in the UK prior to the introduction of novel agents - a response to Koleva et al. (2010): Letter to the editor

Relapsed multiple myeloma in the UK prior to the introduction of novel agents - a response to

Defining the Landscape of Resistance Mutations in the Context of Modern Treatment Protocols for Acute Promyelocytic Leukemia (APL)

Anti-C(w) alloimmunization presenting as hydrops fetalis

Gemtuzumab Ozogamicin with Donor Leucocyte Infusions Is Safe and Effective Therapy for a Subgroup of Relapsed Acute Myeloid Leukaemia and Myelodysplastic Syndrome Following Allogeneic Haemopoietic Stem Cell Transplantation (HSCT)

Editorial

Editorial

Editorial

Anti-Cw alloimmunization presenting as hydrops fetalis

1,2-DIMETHYL-3-HYDROXYPYRID-4-ONE, AN ORALLY ACTIVE CHELATOR FOR TREATMENT OF IRON OVERLOAD

Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one

Aktive Filter

Suchergebnisse filtern